Chinese Journal of Pharmacovigilance ›› 2018, Vol. 15 ›› Issue (5): 319-320.
HUANG Si-chao, YUAN Xiao-bin,ZHONG Jin-song,QIAN Jia-jian
Received:
2018-01-15
Revised:
2018-06-21
Online:
2018-05-20
Published:
2018-06-21
Contact:
陈洁,女,本科,主任药师,药理学及临床药学。E-mail: mlfzp@126.com
CLC Number:
HUANG Si-chao, YUAN Xiao-bin,ZHONG Jin-song,QIAN Jia-jian. One Case of Acute Liver Injury and Thrombocytopenia Induced by Troxerutin and Cerebroprotein Hydrolysate Injection in a Pediatric Patient[J]. Chinese Journal of Pharmacovigilance, 2018, 15(5): 319-320.
Add to citation manager EndNote|Ris|BibTeX
[1] 中国抗癌协会临床肿瘤学协作专业委员会. 肿瘤化疗所致血小板减少症诊疗中国专家共识(2014版) [J]. 中华肿瘤杂志, 2014, 36(11):876-879. [2] 曹婉鑫, 唐瑶, 陈洋. 曲克芦丁药理作用的研究进展[J]. 中国食物与营养, 2015, 21(9):73-75. [3] 邱海军, 马海朋. 曲克芦丁脑蛋白水解物对烟雾病患者神经功能及血小板计数的影响[J]. 中国实用神经疾病杂志, 2016, 19(22):96-98. [4] 中华医学会肝病学分会药物性肝病学组. 药物性肝损伤诊治指南[J]. 临床肝胆病杂志, 2015, 31(11):1752-1769. [5] Chalasani N P, Hayashi P H, Bonkovsky H L, et al. ACG Clinical Guideline: the diagnosis and management of idiosyncratic drug-induced liver injury[J]. Am J Gastroenterol, 2014, 109(7):950-967. [6] 冯亚楠, 刘欣欣, 李永辉, 等. 61例曲克芦丁制剂不良反应的文献分析[J]. 中国药物警戒, 2015, 12(11):683-686. [7] 徐伏莲, 赵志刚. 脑蛋白水解物不良反应文献分析[J]. 中国医院药学杂志, 2007, 27(7):1005-1006. [8] 戴华. 曲克芦丁注射液致肝功能异常[J]. 药物不良反应杂志, 2003, 5(3):202-203. [9] 王斌哲, 王瑞华. 曲克芦丁(维脑路通)致肝损伤1例[J]. 西北国防医学杂志, 2010, 31(4):249. [10] 代东伶, 文飞球, 蔡华波, 等. 儿童重度肝功能损害临床特点分析[J]. 临床儿科杂志, 2015, 33(10):846-849. [11] Amin M D, Harpavat S, Leung D H. Drug-induced liver injury in children[J]. Curr Opin Pediatr, 2015, 27(5):625-633. [12] 都丽萍, 梅丹. 药源性血小板减少症的发病机制和临床表现及防治[J]. 药物不良反应杂志, 2007, 9(6):414-419. |
[1] | LI Xinying, BAO Lei, LI Shuran, ZHAO Ronghua, SUN Jing, XIE Dan, BAO Yanyan, GUO Shanshan, CUI Xiaolan, GENG Zihan. Effect of Shufeng Jiedu Capsules on the Production of Specific Antibodies against Influenza A H1N1 Virus and the Mechanisms [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 841-850. |
[2] | WANG Xinwei, PENG Yifeng, SUN Jing, JI Zuen, BAO Lei, LUO Henglei, GENG Zihan, ZHANG Hujuan, LI Shuran, ZHANG Jingsheng, GUO Shanshan, CUI Xiaolan, ZHAO Ronghua. Effect of Yiye Anti-Influenza Capsules on Pneumonia Induced by Human Coronavirus 229E Infection in Mice [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 851-855. |
[3] | XIE Rui, SUN Qiyue, LI Yanying, ZHANG Jingsheng, ZHAO Ronghua, GUO Shanshan, GENG Zihan, BAO Lei, GAO Shuangrong, CUI Xiaolan, XIE Dan, SUN Jing. Impacts of Shuangshenling Granules on a Cadmium-Induced Chronic Renal Failure Model of Mice [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 856-862. |
[4] | CHEN Siying, DING Xueli, LIU Shujia, ZHANG Xiaomeng, ZHANG Bing, LIN Zhijian. Modeling for Prediction of Cardiotoxicity of Chinese Herbal Medicines [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 869-875. |
[5] | CAI Haili, ZHANG Xiaomeng, LIU Yadi, CHEN Lijuan, WANG Yu, ZHANG Bing. Preventive Strategies for Anthracycline-Induced Cardiotoxicity Using Traditional Chinese Medicine via Ferroptosis Regulation [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 876-882. |
[6] | ZHENG Haiyun, WANG Zhigang, WU Hongwei, WANG Shaonan, WANG Bin. Identification of in vitro and in vivo Chemical Constituents of Buxin Anmian Decoction Based on UPLC-Q Exactive Orbitrap HRMS [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 883-888. |
[7] | SUN Ya, WANG Xu, SUN Zhi, ZHOU Yubing. Dose Analysis of Linezolid in Severe Patients with Sepsis Complicated with Acute Kidney Injury [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 889-895. |
[8] | SHI Qi, WANG Jianxin, WANG Guijie, LU Yueyang, ZHU Jiaxu, GAO Rui. Adjuvant Treatment of Acute Exacerbation of Chronic Obstructive Pulmonary Disease with Qingqi Huatan Pills: a Systematic Review [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 914-919. |
[9] | YING Jie, XU Xiaolong, LI Bo, LIU Tengwen, LIU Qingquan. Clinical Applications of Jinhua Qinggan Granules in the Treatment of Mild Influenza: a Meta-Analysis [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 920-923. |
[10] | KE Xiuqin, HAI Xuewu. 433 Cases of Adverse Drug Reactions Induced by Calcium Dobesilate Capsules [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 924-927. |
[11] | LIANG Jie. 172 Cases of Adverse Drug Reactions Induced by Antineoplastic Drugs [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 928-932. |
[12] | LIU Jiang, CHEN Jie, QIU Sihong, LI Na, ZHOU Ying, CHEN Yonggang, LUO Ji. Analysis of Adverse Drug Event Induced by Omacycline and Moxifloxacin Based on FAERS Databse [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 933-936. |
[13] | ZHAO Mudan, ZHU Minghui, ZHANG Huan, ZHAO Yuanyang, QIN Jing. Pharmaceutical Care of a Case of Diabetic Foot Infection Caused by Proteus penneri [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 937-940. |
[14] | ZHOU Yujie, HUANG Xiaojing, CHEN Mingyue, DU Pengqiang, WANG Aifeng. Two Cases of Severe Thrombocytopenia Caused by Cefoperazone Sulbactam Sodium [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 941-943. |
[15] | CHEN Huabao, LIU Wei, JIANG Ting, ZHENG Lingli, LI Jing. One Case of Acute Withdrawal Syndrome Caused by Naloxone [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 944-946. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||